Injective CEO Says US INJ ETFs Could Launch Before 2027
CEO Eric Chen expects US‑listed INJ exchange‑traded funds to be approved earlier than 2027, with two applications pending.
Injective Protocol CEO Eric Chen said on Tuesday that the United States could see the launch of INJ‑linked exchange‑traded funds earlier than previously anticipated, potentially before 2027. The comment comes as two separate ETF proposals are under review by the U.S. Securities and Exchange Commission.
Pending Applications
Instant Telegram notifications for large on-chain moves.
- 21Shares Injective ETF – a traditional fund tracking the INJ token.
- Canary Staked INJ ETF – a product that would hold staked INJ.
Market Outlook
If approved, the funds would give institutional investors direct exposure to the layer‑1 protocol, expanding liquidity for the $INJ market.
Key facts
- CEO Eric Chen expects launch before 2027.
- Two ETF filings: 21Shares and Canary.
- Approval still pending with the SEC.
Source: theblock.co
This article is for information only and is not investment advice. BullishMarketCap news is produced with AI assistance from public sources and reviewed by our editors; see our editorial policy. Spotted an error? Tell us.
